Invivyd closes $57.5M public offering; net proceeds ~$53.5M for pipeline development

Invivyd, Inc.

Raised ~$57.5M gross ($53.5M net) via 89.2M shares at $0.52/sh and 21.3M pre-funded warrants at $0.5199.
Underwriters' full option exercised; offering led by RA Capital Management and Janus Henderson.
Proceeds to fund VYD2311 clinical program, RSV/measles R&D, and Long COVID studies (SPEAR Study Group).
Dilution: total shares outstanding increases by ~110.6M (including pre-funded warrants exercisable).

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.